Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MSD, Kyorin to Copromote Nasonex Nasal Spray
September 16, 2016
- Asahi Kasei Pharma Gets Japan Rights to Basilea’s Antifungal Agent
September 16, 2016
- Lenvatinib Gets EU Nod for RCC: Eisai
September 16, 2016
- Sawai, Tatsumi Kagaku Tie Up on Kipres Generics
September 16, 2016
- Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
September 14, 2016
- Takeda Returns Rights to MacroGenics’ RA Candidate MGD010
September 14, 2016
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
- “Regulatory Science Center” to Play Important Role to Establish Next-Generation Treatments: JPMA President
September 13, 2016
- Novartis Paid 13.2 Billion Yen to Doctors, Medical Institutions in 2015
September 13, 2016
- Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President
September 12, 2016
- Sales of Ethical Drugs Down 6.4% in July: Crecon Report
September 12, 2016
- Takeda Starts Global PIII for Dengue Vaccine
September 9, 2016
- Aspen Japan Launches Paxil AG
September 9, 2016
- Ono Files Kyprolis for Multiple Myeloma as Combo Therapy with Dexamethasone
September 8, 2016
- Ono Rolls out Multiple Myeloma Treatment Kyprolis
September 8, 2016
- Biogen Japan’s Hemophilia Spinoff to Be Up and Running in Early 2017
September 8, 2016
- Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
September 7, 2016
- Psoriasis Treatment Apremilast Achieves Primary Endpoint in Japan PIIb Trial: Celgene
September 7, 2016
- BIKEN, Kaketsuken to Develop Zika Virus Vaccines from Strain Isolated by Chiba Prefectural Institute of Public Health
September 7, 2016
- Mitsubishi Tanabe Applies for Partial Change to Remicade Dosage to Shorten Administration Interval in Crohn’s Disease
September 7, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…